TNFRSF1A and neoplasm: Infliximab and adalimumab, two immune checkpoint inhibitors that could blockade TNF, TNFRSF1A, and TNFRSF1B, were also included in the network, further highlighting the potential utilities in tumor immunotherapy of TNBC [51].